3 years ago

GenoME Secures £1.4 Million to Advance Early Ovarian Cancer Detection Platform

  • Belfast-based health tech company GenoME has raised £1.4 million in a funding round led by QUBIS, the commercial investment arm of Queen’s University

  • The funding will be used to complete testing of GenoME's diagnostics platform for the early detection of ovarian cancer and seek regulatory approval in the EU

  • The company plans to extend its technology to screen for other types of cancer and potentially expand into other disease areas.

      • ProblemHealthcare

      "Currently, a large proportion of ovarian cancer cases are caught at the later stages of the disease, so patients, unfortunately, have a very poor survival rate. Cancers detected at an earlier stage provide much more opportunity for intervention and improve patient survival."

      Solution

      "GenoME is developing a diagnostics platform for the early detection of ovarian cancer. The platform will use a combination of genetic and other biomarkers to identify women at high risk of developing the disease. This will allow for earlier intervention and potentially improve patient survival."

      Covered on